HPTN 069: A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF)
Study Location:
Baltimore
Topic:
HIV
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT01505114?term=HPTN+069&rank=1
IRB#:
NA_00066263
Coordinator:
Robin Worrell-Thorne
Enrollment:
Closed
Trial Period:
Completed
HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four antiretroviral (ARV) drug regimens used as pre-exposure prophylaxis (PrEP) to prevent HIV transmission in a population of at-risk men who have sex with men (MSM) and in at-risk women.
HIV-uninfected at-risk MSM and at-risk women > 18 years.
410-955-2898